BR0010034A - Utilização de um vetor, processo de preparação de um medicamento útil para a prevenção, a melhoria e/ou o tratamento da hipertensão arterial pulmonar, e, composição farmacêutica - Google Patents

Utilização de um vetor, processo de preparação de um medicamento útil para a prevenção, a melhoria e/ou o tratamento da hipertensão arterial pulmonar, e, composição farmacêutica

Info

Publication number
BR0010034A
BR0010034A BR0010034-0A BR0010034A BR0010034A BR 0010034 A BR0010034 A BR 0010034A BR 0010034 A BR0010034 A BR 0010034A BR 0010034 A BR0010034 A BR 0010034A
Authority
BR
Brazil
Prior art keywords
vector
prevention
treatment
arterial hypertension
pulmonary arterial
Prior art date
Application number
BR0010034-0A
Other languages
English (en)
Inventor
Serge Adnot
Didier Branellec
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9905272A external-priority patent/FR2792531B1/fr
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Publication of BR0010034A publication Critical patent/BR0010034A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"UTILIZAçãO DE UM VETOR, PROCESSO DE PREPARAçãO DE UM MEDICAMENTO úTIL PARA A PREVENçãO, A MELHORIA E/OU O TRATAMENTO DA HIPERTENSãO ARTERIAL PULMONAR, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se à utilização de um vetor compreendendo um ácido nucleico codificando para um fator angiogênico para a prevenção, a melhoria e/ou o tratamento da hipertensão arterial pulmonar.
BR0010034-0A 1999-04-26 2000-04-21 Utilização de um vetor, processo de preparação de um medicamento útil para a prevenção, a melhoria e/ou o tratamento da hipertensão arterial pulmonar, e, composição farmacêutica BR0010034A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9905272A FR2792531B1 (fr) 1999-04-26 1999-04-26 Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
US13973499P 1999-06-18 1999-06-18
PCT/FR2000/001060 WO2000065043A1 (fr) 1999-04-26 2000-04-21 Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire

Publications (1)

Publication Number Publication Date
BR0010034A true BR0010034A (pt) 2002-01-15

Family

ID=26234932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010034-0A BR0010034A (pt) 1999-04-26 2000-04-21 Utilização de um vetor, processo de preparação de um medicamento útil para a prevenção, a melhoria e/ou o tratamento da hipertensão arterial pulmonar, e, composição farmacêutica

Country Status (17)

Country Link
US (1) US20020086004A1 (pt)
EP (1) EP1173564A1 (pt)
JP (1) JP2002543097A (pt)
KR (1) KR20020001846A (pt)
CN (1) CN1376197A (pt)
AU (1) AU782833B2 (pt)
BR (1) BR0010034A (pt)
CA (1) CA2370404A1 (pt)
CZ (1) CZ20013813A3 (pt)
HU (1) HUP0200961A3 (pt)
IL (1) IL145834A0 (pt)
MX (1) MXPA01010849A (pt)
NO (1) NO20015223D0 (pt)
NZ (1) NZ515233A (pt)
PL (1) PL351114A1 (pt)
SI (1) SI20750A (pt)
WO (1) WO2000065043A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
MXPA02003434A (es) * 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
CA2444632A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
KR100697321B1 (ko) * 2005-07-27 2007-03-20 박기랑 ＶＥＧＦ－Ａ, ＶＥＧＦ－Ｂ 및 ＶＥＧＦ－Ｃ의 안티센스ｃＤＮＡ를 함유하는 재조합 아데노-연관바이러스（ｒＡＡＶ） 및 이를 함유하는 대장암, 방광암및/또는 폐암 특이적 유전자 치료제
EP2446899B1 (en) * 2009-06-25 2020-09-30 Bioleaders Corporation Adjuvant composition comprising (poly-gamma-glutamate)-chitosan nanoparticles
CN105833248A (zh) * 2016-04-27 2016-08-10 温州医科大学附属第医院 成纤维细胞生长因子21的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717495B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
EP0880587A1 (en) * 1996-02-15 1998-12-02 Chiron Corporation Gene therapy method using fgf-5
EP0941116B1 (en) * 1996-11-01 2005-01-19 Ark Therapeutics Limited Use of vegf for the manufacture of a medicament for the treatment or prevention of intimal hyperplasia and delivery device
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Also Published As

Publication number Publication date
IL145834A0 (en) 2002-07-25
AU782833B2 (en) 2005-09-01
PL351114A1 (en) 2003-03-24
HUP0200961A3 (en) 2004-11-29
SI20750A (sl) 2002-06-30
CZ20013813A3 (cs) 2002-02-13
NZ515233A (en) 2004-08-27
CA2370404A1 (fr) 2000-11-02
US20020086004A1 (en) 2002-07-04
NO20015223L (no) 2001-10-25
EP1173564A1 (fr) 2002-01-23
HUP0200961A2 (hu) 2002-07-29
CN1376197A (zh) 2002-10-23
AU4301700A (en) 2000-11-10
KR20020001846A (ko) 2002-01-09
JP2002543097A (ja) 2002-12-17
MXPA01010849A (es) 2002-11-07
WO2000065043A1 (fr) 2000-11-02
NO20015223D0 (no) 2001-10-25

Similar Documents

Publication Publication Date Title
BR9713147A (pt) Benzamidoaldeìdo, uso do mesmo, benzamida, e, preparação medicamentosa para administração oral, parenteral ou intraperitoneal.
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
HUP0002224A1 (hu) Virusellenes hatású benzimidazol-származékok
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
ITRM990338A0 (it) Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
BR0211807A (pt) Derivados ativos amino-ftalazinona como inibidores de cinase, processo para sua preparação e composições farmacêuticas para os mesmos
DE69636531D1 (de) Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
BG101118A (en) Therapeutical compounds
DE69818707D1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
BR9911072A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
BR9814375A (pt) Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR9809304A (pt) "formulações de proteìna c ativada"
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
TR200001542T2 (tr) Mide fundusunu gevşetici özelliklere sahip (benzodioksan, benzofuran veya benzopiran) türevleri.
BR0010034A (pt) Utilização de um vetor, processo de preparação de um medicamento útil para a prevenção, a melhoria e/ou o tratamento da hipertensão arterial pulmonar, e, composição farmacêutica
EE200300476A (et) 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon
BR9913135A (pt) Formulação oral
BR0113590A (pt) 7-oxo-piridopirimidinas
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
WO2002062304A3 (de) Kosmetische und/oder pharmazeutische mittel acylierte aminosäure und proteinkondensat enthaltend.

Legal Events

Date Code Title Description
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1991 DE 03/03/2009 POR TER SIDO INDEVIDO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009.